Vertex Pharmaceuticals (NASDAQ: VRTX) has experienced a dynamic few years, establishing itself as a leader in the cystic fibrosis (CF) treatment sector while successfully expanding into new therapeutic areas. The company received approval for Casgevy, a treatment for blood disorders, and Journavx, a non-opioid pain management solution. Moreover, Vertex continued to solidify its position in CF with another new approval. Recently, investors received promising news regarding Povetacicept, its candidate for treating IgA nephropathy, which successfully met its clinical goals; the company plans to present it to regulators by month's end. Given this positive momentum, could Vertex's stock, currently priced around $480, soar to $600—a 25% increase that would elevate its market value from $121 billion to $152 billion? Such growth seems plausible, depending on the company's ability to deliver favorable developments that bolster investor confidence. For instance, approval of Povetacicept could contribute significantly to this target, alongside the anticipated strong performance of new treatments like Casgevy and Journavx. Notably, Vertex may weather broader market headwinds well, as investors often flock to healthcare stocks in challenging times. Priced at 24 times projected earnings, Vertex looks appealing, leaving the door open for potential growth toward $600 in the near future.